Clinical Trials on Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Total 7829 results

Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...

United States
Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Advanced Squamous Non-Small Cell Lung Carcinoma

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
M.D. Anderson Cancer Center

Terminated

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung... and other conditions

United States
Zhejiang Teruisi Pharmaceutical Inc.

Unknown

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (NSCLC)

Advanced Non-squamous Non-small-cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Western Regional Medical Center

Terminated

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

United States
Qianfoshan Hospital

Recruiting

First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial (SPBPDC)

Advanced Non-squamous Non-Small-Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
University of Chicago
Genentech, Inc.

Completed

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC (AVF4759)

Advanced Non-squamous Non-Small Cell Lung Cancer

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Xinqiao Hospital of Chongqing

Withdrawn

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients (XQonc-007)

Advanced Non-squamous Non-small-cell Lung Cancer

China
Xinqiao Hospital of Chongqing

Withdrawn

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Advanced Non-squamous Non-small-cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Advanced Non-squamous Non-small Cell Lung Cancer

China
Chang Gung Memorial Hospital
Taiwan Chest Disease Association

Completed

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Advanced Non-Squamous Non-Small Cell Lung Cancer

Taiwan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Erasca, Inc.

Completed

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2)

Advanced Non-squamous Non-small-cell Lung Cancer

United States
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
NantCell, Inc.

Terminated

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Spain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
The Netherlands Cancer Institute
Daiichi Sankyo, Inc.

Not yet recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
Sichuan University
Shanxi Provincial Cancer Hospital; Mianyang Central Hospital; Chengdu First people... and other collaborators

Not yet recruiting

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

Advanced Squamous Non-Small-Cell Lung Cancer
University of Texas Southwestern Medical Center

Recruiting

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Advanced Squamous Non Small Cell Lung Cancer

United States
Sinocelltech Ltd.

Unknown

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer (sNSCLC)

Advanced Squamous Non-small Cell Lung Cancer
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

Non-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung Cancer

Brazil, Canada
European Organisation for Research and Treatment...

Withdrawn

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (SOLUTION)

Squamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Squamous Carcinoma | Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States, Guam
The First Affiliated Hospital of Xinxiang Medical...

Not yet recruiting

Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Locally Advanced Squamous Non-small Cell Lung Cancer
University of California, Davis
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

KRAS Gene Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...

United States
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Guangdong Association of Clinical Trials

Unknown

Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC

Advanced Non-squamous NSCLC

China
Shanghai Henlius Biotech

Active, not recruiting

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Squamous-cell Non-small Cell Lung Cancer

China
Pfizer

Terminated

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Advanced Non-squamous NSCLC

China
LanZhou University
General Hospital of Ningxia Medical University

Unknown

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC
Ribon Therapeutics, Inc.

Active, not recruiting

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Advanced Squamous Non-Small Cell Lung Carcinoma

United Kingdom, United States, Israel, Spain
Amgen

Terminated

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Advanced Non-squamous NSCLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma and other conditions

United States
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)

Carcinoma, Non-Squamous Non-Small Cell Lung

United States, Israel, Belgium, Canada, Spain, Germany, Italy, France
National Cancer Institute (NCI)

Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Adenocarcinoma | Advanced Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Advanced NSCLC | Adenosquamous Carcinoma

United States

Clinical Trials on Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations